stoxline Quote Chart Rank Option Currency Glossary
  
Centessa Pharmaceuticals plc (CNTA)
16.26  -0.81 (-4.75%)    02-18 16:00
Open: 17.25
High: 17.47
Volume: 974,717
  
Pre. Close: 17.07
Low: 15.685
Market Cap: 2,141(M)
Technical analysis
2025-02-18 4:42:48 PM
Short term     
Mid term     
Targets 6-month :  20.22 1-year :  22.29
Resists First :  17.31 Second :  19.09
Pivot price 17.41
Supports First :  14.43 Second :  12.01
MAs MA(5) :  17.24 MA(20) :  17.18
MA(100) :  16.58 MA(250) :  13.09
MACD MACD :  0.1 Signal :  0.2
%K %D K(14,3) :  40.7 D(3) :  52.4
RSI RSI(14): 44
52-week High :  19.09 Low :  7.75
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CNTA ] has closed above bottom band by 13.5%. Bollinger Bands are 30.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 17.49 - 17.63 17.63 - 17.73
Low: 15.41 - 15.56 15.56 - 15.65
Close: 16.07 - 16.3 16.3 - 16.45
Company Description

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Headline News

Tue, 18 Feb 2025
Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Update - MarketBeat

Sat, 15 Feb 2025
Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 30,526 Shares of Stock - MarketBeat

Mon, 10 Feb 2025
Centessa Pharmaceuticals officer sells shares worth $588,943 - MSN

Fri, 07 Feb 2025
Possible Bearish Signals With Centessa Pharmaceuticals Insiders Disposing Stock - Simply Wall St

Tue, 28 Jan 2025
Centessa Pharmaceuticals chief business officer sells shares worth $193,429 - Investing.com

Tue, 28 Jan 2025
Exclusive: Centessa's Strategic Move - All Eyes on These 4 Game-Changing Healthcare Events - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 132 (M)
Held by Insiders 9.023e+007 (%)
Held by Institutions 1.2 (%)
Shares Short 3,630 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.613e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 358.8 %
Return on Equity (ttm) -20.5 %
Qtrly Rev. Growth 6.85e+006 %
Gross Profit (p.s.) 0
Sales Per Share -27.8
EBITDA (p.s.) 4.47712e+006
Qtrly Earnings Growth -1.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -130 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.59
Price to Cash Flow 6.56
Stock Dividends
Dividend 0
Forward Dividend 3.05e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android